Amicus Therapeutics Inc [FOLD] Stock trading around $10.60 per share: What’s Next?

- Advertisements -

Amicus Therapeutics Inc [NASDAQ: FOLD] plunged by -$0.06 during the normal trading session on Thursday and reaching a high of $10.76 during the day while it closed the day at $10.60. The company report on November 8, 2023 at 7:00 AM that Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates.

3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER.

- Advertisements -

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Amicus Therapeutics Inc stock has also gained 6.27% of its value over the past 7 days. However, FOLD stock has declined by -17.25% in the 3 months of the year. Over the past six months meanwhile, it has lost -7.91% and lost -13.19% year-on date.

The market cap for FOLD stock reached $3.11 billion, with 293.25 million shares outstanding and 284.40 million shares in the current float. Compared to the average trading volume of 2.32M shares, FOLD reached a trading volume of 3234917 in the most recent trading day, which is why market watchdogs consider the stock to be active.

- Advertisements -

Here’s what leading stock market gurus have to say about Amicus Therapeutics Inc [FOLD]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for FOLD shares is $17.90 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on FOLD stock is a recommendation set at 1.83. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Amicus Therapeutics Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on September 09, 2022.

The Average True Range (ATR) for Amicus Therapeutics Inc is set at 0.55, with the Price to Sales ratio for FOLD stock in the period of the last 12 months amounting to 8.35. The Price to Book ratio for the last quarter was 23.12, with the Price to Cash per share for the same quarter was set at 0.96.

- Advertisements -

FOLD stock trade performance evaluation

Amicus Therapeutics Inc [FOLD] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.27. With this latest performance, FOLD shares dropped by -0.47% in over the last four-week period, additionally sinking by -7.91% over the last 6 months – not to mention a drop of -9.17% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FOLD stock in for the last two-week period is set at 45.65, with the RSI for the last a single of trading hit 45.86, and the three-weeks RSI is set at 45.25 for Amicus Therapeutics Inc [FOLD]. The present Moving Average for the last 50 days of trading for this stock 11.40, while it was recorded at 10.54 for the last single week of trading, and 12.08 for the last 200 days.

Amicus Therapeutics Inc [FOLD]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Amicus Therapeutics Inc [FOLD] shares currently have an operating margin of -62.09 and a Gross Margin at +86.65. Amicus Therapeutics Inc’s Net Margin is presently recorded at -71.85.

Return on Total Capital for FOLD is now -30.91, given the latest momentum, and Return on Invested Capital for the company is -36.21. Return on Equity for this stock declined to -109.93, with Return on Assets sitting at -29.04. When it comes to the capital structure of this company, Amicus Therapeutics Inc [FOLD] has a Total Debt to Total Equity ratio set at 367.44. Additionally, FOLD Total Debt to Total Capital is recorded at 78.61, with Total Debt to Total Assets ending up at 62.43. Long-Term Debt to Equity for the company is recorded at 360.49, with the Long-Term Debt to Total Capital now at 77.12.

Reflecting on the efficiency of the workforce at the company, Amicus Therapeutics Inc [FOLD] managed to generate an average of -$488,777 per employee. Receivables Turnover for the company is 5.54 with a Total Asset Turnover recorded at a value of 0.40.Amicus Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.40 and a Current Ratio set at 2.73.

Amicus Therapeutics Inc [FOLD]: Institutional Ownership

The top three institutional holders of FOLD stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in FOLD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in FOLD stock with ownership which is approximately 5.7994%.

- Advertisements -

Leave a Reply

Your email address will not be published. Required fields are marked *